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Review
Placenta-Derived Cells for Acute
Brain Injury
Francesca Pischiutta1, Eliana Sammali1,2, Ornella Parolini3,4,
Hilary V. O. Carswell5, and Elisa R. Zanier1
Abstract
Acute brain injury resulting from ischemic/hemorrhagic or traumatic damage is one of the leading causes of mortality and
disability worldwide and is a significant burden to society. Neuroprotective options to counteract brain damage are very
limited in stroke and traumatic brain injury (TBI). Given the multifaceted nature of acute brain injury and damage progression,
several therapeutic targets may need to be addressed simultaneously to interfere with the evolution of the injury and improve
the patient’s outcome. Stem cells are ideal candidates since they act on various mechanisms of protection and repair,
improving structural and functional outcomes after experimental stroke or TBI. Stem cells isolated from placenta offer
advantages due to their early embryonic origin, ease of procurement, and ethical acceptance. We analyzed the evidence for
the beneficial effects of placenta-derived stem cells in acute brain injury, with the focus on experimental studies of TBI and
stroke, the engineering strategies pursued to foster cell potential, and characterization of the bioactive molecules secreted by
placental cells, known as their secretome, as an alternative cell-free strategy. Results from the clinical application of placenta-
derived stem cells for acute brain injury and ongoing clinical trials are summarily discussed.
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The Rationale for Using Placenta-Derived
Cells for Acute Brain Injury
Acute brain injury, resulting from traumatic brain injury
(TBI), ischemic stroke, or intracerebral hemorrhage (ICH),
is associated with high rates of short-term mortality and
long-term disability worldwide1. Independent of its etiology
(vascular occlusion, bleeding, or mechanical injury), brain
damage is amplified after the primary insult, with the activa-
tion of genomic, cellular, and/or biochemical processes that
interact in a complex network leading to delayed cellular
dysfunction and death. Although the extensive effects of
these events and the abundance of targets offer the potential
for therapeutic interventions, so far there is no pharmacolo-
gical treatment that can reverse the pathologic cellular cas-
cades and improve the outcome. Thus, there is a pressing
need for therapeutic approaches aimed at protecting and
repairing the injured brain.
Stem cells, with their ability to act simultaneously on
multiple targets, driving the damaged microenvironment
from a toxic to a more protective/regenerative activation state,
are a promising strategy2–6. Stem cells have been isolated
from almost all body organs, raising the question of the best
source for each specific pathology, since heterogeneous
effects have been observed depending on the source.
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According to their tissue origin, stem cells display spe-
cific differences at transcriptional and proteomic levels7,8.
Moreover, aging negatively affects stem/progenitor cell
properties9,10, reducing their proliferation and differentiation
capacity11,12, their immunomodulatory effects13, and their
therapeutic potential14,15. Thus, stem/progenitor cells from
placenta are of special interest in a translational perspective,
mainly on account of their reduced immunogenicity and high
immunomodulatory potential and their broad plasticity16,17.
The placenta is a fetomaternal organ. The fetal placental
tissues include the amniotic and chorionic membranes, the
umbilical cord, and the chorionic villi. The maternal compo-
nent is known as decidua16,18. All these placental tissues/
fluids are easily available after birth, without invasive pro-
cedures, and their use is free from ethical issues.
This review examines the evidence for placenta-derived
stem cell therapy for acute brain injury in experimental set-
tings, with a focus on TBI, stroke, and ICH. We not only
discuss efficacy but also the mechanisms of action and the
engineering strategies used to amplify stem cell potency.
One section will deal with the discussion of the bioactive
molecules secreted by placental cells and the potential use of
the secretome as a cell-free, better defined therapeutic strat-
egy. Lastly, results from the clinical application of placenta-
derived stem cells for acute brain injury and ongoing clinical
trials will be discussed.
This is a narrative, nonsystematic, comprehensive review
of the literature. The search string run in the PubMed data-
base in January 2017 was as follows: ((“traumatic brain
injury” OR “brain trauma” OR “head trauma”) OR (“Brain
Ischemia”[Mesh] OR “Stroke”[Mesh] OR stroke OR “brain
ischemia”)) AND ((“Stem Cells”[Mesh] OR “stem cells”
OR “stem cell” OR “stromal cells” OR “stromal cell”) AND
(“placenta” OR “amnion” OR “amniotic” OR “cord blood”
OR “umbilical” OR “chorion” OR “chorionic” OR
“trophoblasts” OR “decidua”)). We screened 301 papers for
title, abstract, and full text, finally selecting 139 original
articles and 60 reviews. Five of the original articles were
clinical studies and 134 experimental, of which 21 focused
on TBI, 93 on cerebral ischemia, 16 on neonatal/infant
stroke, and 4 on ICH. Among papers on stroke, those using
models of heatstroke or diabetes were outside the remit of
this review and were therefore not used. Thirty-five papers
were added for analysis of the secretome, based on our own
files or reference lists of previously reviewed articles.
In the majority of studies, cells were of human (h) origin,
with very few using rat (r) or mouse (m) cells. Cells were
isolated from different placental tissues and fluids including
umbilical cord blood (UCB), umbilical cord tissue (UCT),
amnion (A) and amniotic fluid (AF). The specific subtypes
of cells used in the field of acute brain injury are listed in
Figure 1. We found no study using cells from chorion, tro-
phoblasts, or decidua.
Placenta-Derived Cell Transplantation
for TBI
The literature concerning the use of placenta-derived stem
cells in experimental models of TBI shows more widespread
use of cells isolated from the UCB or tissue19–27 than cells
from the amnion or AF28,29. No papers were found using
cells from chorion, trophoblasts, or decidua.
The first paper using human umbilical cord blood stem
cells (hUCB-SCs) was published by Lu and colleagues19
who used 2 million hUCB-SCs, without selecting any spe-
cific population. Cells were intravenously infused in rats,
24 h after controlled cortical impact (CCI) brain injury and
improved sensorimotor function from 2 wk post-TBI19.
After this first experiment, the use of placenta-derived stem
cells focused on investigation of the effects of specific sub-
populations (endothelial, hematopoietic, or mesenchymal
stromal cells [MSCs]) isolated from the hUCB.
Figure 1. Specific subtypes of placenta-derived cells used for experimental acute brain injury.
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The endothelial progenitors were selected with the aim of
promoting vascular repair and stimulating neoangiogenic pro-
cesses. Both systemic22 and local (intracerebroventricular
[ICV] infusion)23 transplantation of hUCB-derived endothe-
lial progenitor cells (hUCB-EPCs) in traumatized rodents can
increase microvascularization in the injured brain and angio-
genic processes22,23, preserving blood–brain barrier (BBB)
integrity23 and reducing brain edema23. ICV-transplanted
hUCB-EPCs integrated into the brain microvasculature23, but
when intravenously (IV) infused, the number of integrated
hUCB-EPCs was scanty and the neovascularization was
mostly due to the release of proangiogenic factors22.
Similar results on the vascular compartment have been
obtained with hUCB-derived hematopoietic subpopulations
(CD34þ or CD45þ)21,24, with an increase in cerebral perfu-
sion pressure21, stimulation of vascular endothelial growth
factor (VEGF) production24, and increased angiogenesis21.
Besides vascular effects, hUCB-CD34þ cells also stimulated
neurogenesis, with increases in the amounts of newly gen-
erated neurons (BrdUþ/NeuNþ cells), induced anti-
inflammatory effects, lowering serum levels of proinflam-
matory cytokines (tumor necrosis factor a [TNF-a] and
intercellular adhesion molecule 1 (Icam-1)) and increasing
the anti-inflammatory ones (interleukin [IL] 10), and
decreased toxic oxidizing radicals (NOx )
21. Overall func-
tional improvement in both sensorimotor21–24 and
cognitive22,23 deficits induced by hUCB endothelial or
hematopoietic cells has been observed, together with a
reduction in contusion volume21,22,24. It is not clear, how-
ever, whether these nonvascular effects are directly pro-
moted by the transplanted cells or are an indirect
consequence of the vascular rescue.
The other subpopulation widely used for TBI are MSCs
isolated from hUCB20 or hUCT25–27,30. Since the data avail-
able do not allow for a distinction of enhanced efficacy of the
MSCs depending on the different regions of the umbilical
cord, they are collectively referred to as umbilical-MSCs.
Systemic25,27 and local20,26 transplantation of MSCs in TBI
rodents was able to induce functional improvement in sen-
sorimotor20,25–27 and cognitive20,26,27 deficits and reduce the
contusion volume20,26. Transplanted umbilical-MSCs were
found in the lesion site and their migration toward the injured
tissue seemed to be driven by the stromal cell-derived factor
1/ C-X-C chemokine receptor type 4 (SDF-1/CXCR4) path-
way25; however, the number of cells surviving after trans-
plantation gradually drops20.
The various protective mechanisms elicited by trans-
planted cells involve different pathways. MSCs reduce
brain edema26, lower the number of apoptotic cells in the
damaged area25, boost the expression of neurotrophic fac-
tors20,26, stimulate endogenous neurogenesis25–27, and have
immunoregulatory effects, reducing serum markers of
proinflammatory mediators (IL-1, interferon [IFN] g, anti-
brain antibody) and increasing anti-inflammatory ones (IL-
10 and transforming growth factor b)30. Umbilical-MSCs
also shift activated microglial cells in the pericontusional
tissue toward a nonphagocytic phenotype with protective
and healing functions20.
The amniotic source for stem cell therapy has been
less investigated for TBI, with only 2 papers pub-
lished28,29. Chen and colleagues used human amnion–
derived multipotent progenitor cells (hAMPCs) and
transplanted 2 million cells ICV immediately after
penetrating ballistic-like brain injury in rats28. Trans-
planted cells reduced axonal degeneration in the corpus
callosum and in the thalamus. Labeled hAMPCs
migrated from the subventricular zone to the corpus
callosum but not to the thalamus, and there was no evi-
dence of differentiation toward neuronal lineage, sug-
gesting that the effects of these cells may result from
a continuous supply of secreted bioactive factors28.
Our group has provided evidence of the protective effects
of human amnion membrane-derived MSCs (hAMSCs) in a
mouse model of TBI modeled by controlled cortical impact
(CCI)29. We compared the effects of ICV and IV trans-
planted cells 24 h after TBI in mice. Only ICV transplanted
cells were found in the brain at acute stages after injury, but
ICV and IV transplanted hAMSCs induced functional
improvement in sensorimotor deficits to similar extents.
Functional improvement was associated with histological
protective modifications, such as neuronal and vessel rescue
in the pericontusional cortex and the stimulation of endogen-
ous neurogenesis29.
To summarize, the literature regarding the use of
placenta-derived cell therapy for TBI varies widely, with
different tissues of origin, isolation protocols, and subpopu-
lations. Although it is hard to compare the therapeutic effects
obtained in different laboratories, it is clear that infused cells
have pleiotropic action on multiple targets, inducing protec-
tive/regenerative environmental changes and stimulating
endogenous neuroprotective mechanisms by autocrine/
paracrine factors. The presence of cells in the lesioned brain
seems to be unnecessary to confer the protection, thus posing
the basis for the development of a cell-free strategy using
the stem cell secretome. This topic will be discussed
in the section “Placenta-Derived Cell Secretome: Toward
Cell-Free Therapy.”
Placenta-Derived Cell Transplantation
for Stroke
The first preclinical use of placenta-derived cells for stroke
dates back to 200131,32. Chen and colleagues reported that IV
infused hUCB-SCs after middle cerebral artery occlusion
(MCAO) in rats improved functional recovery31, and Okawa
and colleagues described the permanence of hippocampal
transplanted rat-derived AECs at the site of injection, 5 wk
after stroke in gerbils32. Since then several studies have
explored the efficacy and mechanisms of action of
placenta-derived cells after brain ischemia. As with TBI,
we also noted for stroke that cells derived from an umbilical
source have been investigated far more than amniotic cells,
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and we did not find any studies that used cells isolated from
the chorion, trophoblast, or decidua.
The mechanisms of hUCB cell-induced recovery after
stroke have been investigated with the aim of establishing
whether transplanted cells must actually enter the brain to be
effective. When hUCB-SCs were IV infused 24 to 48 h after
MCAO, viable cells were found in the brain and improved
functional recovery was reported31,33. Efficiency was dose
dependent and higher when compared to intracranial admin-
istration at the same time point33. This dose-related effect
was also found for hUCT-derived cells34. The ability of
hUCT-MSCs to differentiate into neural phenotypes has
been shown in vitro35; however, transdifferentiation of
hUCT-MSCs into fully functional neurons after in vivo acute
brain injury has never been demonstrated and mechanisms
other than engraftment appear to mediate the restorative
effects after hUCT-MSC infusion36,37.
Despite the above evidence, along with the observation
that hUCB-SCs have potent migratory capacity in response
to ischemic brain injury38, probably through chemokine
SDF-1/CXCL1239, there is evidence that systemically admi-
nistered cells do not need to enter the brain to induce func-
tional recovery after MCAO40. Several studies indicate that
hUCB cells induce restorative effects after stroke through
the secretion of trophic factors41. In addition, hUCT-MSCs
secrete human brain–derived neurotrophic factor (BDNF),
neutrophil-activating protein-2 (NAP-2), angiopoietin-2
(Ang-2), CXCL16, platelet-derived growth factor-AA
(PDGF-AA), basic fibroblast growth factor (hVEGFR-3),
and human vascular endothelial growth factor receptor-337
(see also “Placenta-Derived Cell Secretome: Toward Cell-
Free Therapy” section). Although most studies show these
trophic factors induce angiogenesis, neurogenesis, and
synaptogenesis at the site of injury after adult and perinatal
ischemia34,42,43, the role of hUCB-SCs in restoring spleen
weight and splenic CD8þ T-cell counts after MCAO has
been highlighted44, indicating a role in dampening the sys-
temic inflammatory response after stroke. The immunomo-
dulatory effects of hUCB cells are established in other
inflammatory conditions and are potential mechanisms for
mediating restoration after stroke. hUCB-SCs were able to
reduce ischemia-induced infiltration of granulocytes, mono-
cytes, and CD3þ T cells and activation of astrocytes and
microglia in adults45–47 and pups48, in addition to reducing
proinflammatory cytokines and nuclear factor kB activity46
after stroke, all of which may contribute to the resolution of
the inflammatory response after stroke and facilitate postis-
chemic plasticity.
In terms of the subpopulations, hUCB-CD34þ cells have
been prominently investigated in stroke models and have
been shown to reduce brain damage in newborns49 and to
induce behavioral recovery50,51which is enhanced in CD34þ
cells overexpressing glial cell line–derived neurotrophic
factor (GDNF)52. hUCB-CD34þ cells have also been shown
to be responsible for the angiogenic and neurogenic effects
observed after hUCB-SC infusion42, although hUCB-
CD34 cells were just as effective50. Boltze and colleagues
not only found that hUCB-CD34þ and CD34 cells had
similar behavioral effects, but also that human umbilical
cord blood-derived mononuclear cells (hUCB-MNCs) were
more effective53. Among the different cells in hUCB-MNCs
(immature T and B cells, monocytes, and stem cells), mono-
cytes were found to have the most marked effects on improv-
ing functional recovery and reducing infarct54. Several
studies have also indicated the therapeutic benefits of hUCB-
or hUCT-derived MSCs after stroke. hUCB-MSCs reduced
infarction lesion size after cerebral ischemia in adult rats55
and dogs56 as well as rat neonates57,58. hUCT-MSCs also
improved functional recovery in rats after MCAO37, possi-
bly by reducing peripheral and cerebral proinflammatory
cytokines, an observation reported for both hUCB-
MSCs57,59 and hUCT-MSCs60.
Despite this wealth of evidence on the comprehensive
efficacy of hUCB cells in stroke, a number of studies show
a lack of effects61–63, so further research into different stor-
age and processing conditions is still needed to confirm
the therapeutic potential of hUCB- and hUCT-derived cells
in stroke.
As regards amniotic cells, the epithelial population
amniotic epithelial cells (AECs), isolated from rat32 or
human64 tissues, can migrate to the site of ischemic injury32
and improve functional recovery after MCAO64. hAMSCs
can also improve functional recovery after MCAO65,66,
accelerated by overexpression of BDNF67.
AF stem cells were also shown to promote functional
recovery after MCAO68, reducing ischemic damage and pro-
moting neurogenesis69, and have been used for reprogram-
ming into induced pluripotent stem cells (iPSCs)70.
To summarize, the current evidence for the potential of
placenta-derived cell therapy for stroke is promising.
Despite the different protocols and subpopulations tested,
and the consensus needed on optimum storage and process-
ing conditions, the literature indicates that placenta-derived
stem cells improve functional recovery after MCAO, most
likely by promoting angiogenesis and neurogenesis and
through potent immunomodulatory effects that contribute
to the resolution of the inflammatory response after stroke
and facilitate postischemic plasticity.
Placenta-Derived Cell Transplantation
for ICH
In the experimental models of ICH, hUCB and hUCT are the
only placental sources that have been investigated71–73.
hUCB-MNCswere tested in a dose-dependent study71 in order
to study the effects of 4, 8, or 16 million IV infused cells 1 d
after intrastriatal ICH. All transplanted groups showed
similar improvement in sensorimotor function after 1 wk.
Cells migrated selectively to the hemorrhagic area in the right
striatum, with more cells found in the highest dose group.
Similarly, the lesion volume decreased in all transplanted
groups compared to control, with a dose-dependent effect.
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Two studies investigated the effects of hUCB-MSCs72 or
hUCT-MSCs73. ICV infusion of 500,000 hUCB-MSCs, 2 d
after intrastriatal ICH, improved sensorimotor function, with
a reduction in the lesion volume 4 wk after transplant72.
Cells were found in proximity to the hemorrhagic area 3 d
after injection, but they disappeared at later time points
(4 wk), with a nonsignificant tendency toward reduction in
proinflammatory markers (TNF-a, cyclooxygenase-2
(COX-2) microglial activation, and neutrophil infiltration).
Xie and colleagues compared the effect of intracerebrally
(200,000 cells) or IV (2 million cells) infused hUCT-
MSCs after intrastriatal ICH, observing similar protection
on sensorimotor deficits and lesion volume73. Four weeks
later, intracerebrally transplanted hUCT-MSCs were still
clustered in the injection site, near the hemorrhagic region,
while only a small part of the IV transplanted cells could be
found in the brain. Only rats that intracerebrally received
hUCT-MSCs had enhanced vascular density in the peri-ICH
regions of the ipsilateral hemisphere, which was attributed to
the limited number of IV transplanted cells that migrated to
the damaged tissue. Given the similarity of the functional
benefit, it may well be that locally and systemically trans-
planted cells act through different mechanisms and that com-
bining the two may exert synergistic effects.
Manipulation of Placenta-Derived Stem
Cells and/or the Use of Survival-Promoting
Scaffolds
To optimize the therapeutic efficacy of transplanted cells,
different combinatory strategies have been employed, includ-
ing the use of scaffolds (spatially guiding tissue regeneration),
the genetic modification (to overexpress specific factors or
promote survival), and delivery of different biomolecules
(trophic factors, modulators of inflammatory molecules).
With the aim of enhancing cell engraftment and differ-
entiation, in vitro neuronal commitment prior to in vivo
transplantation has also been tried74,75. hUCT-MSCs
untransdifferentiated or transdifferentiated into neural-like
cells (hUCT-MSC-NSCs) were resuspended in 10 mL Matri-
gel and transplanted into the ipsilateral hippocampus of rats,
7 d after TBI induced by weight drop impact model74. Only
6% to 7% of the transplanted cells were found in the brain 28
d after transplantation, with no differences in survival rates
between hUCT-MSCs and hUCT-MSC-NSCs. Both treated
groups showed a reduction in contusion volume and an
improvement in cognitive deficits compared to control
groups. However, untransdifferentiated hUCT-MSCs
induced a better outcome than hUCT-MSC-NSCs. In vitro
experiments showed that hUCT-MSCs secrete more neuro-
trophic factors (BDNF and neurotrophin-3 [NT-3]) than
hUCT-MSC-NSCs, suggesting that transdifferentiation
before use may not provide any advantage.
Two years later, the same authors did a similar analysis
using hAMSCs undifferentiated or in vitro transdifferentiated
into neural stem-like cells (hAMSC-NSCs)75. Cellswere trans-
planted in TBI rats using a similar protocol, with the only
exception that cells were infused earlier (4 d). Both trans-
planted groups showed improvement in sensorimotor and
cognitive functions compared to controls, but hAMSC-NSC
transplantation resulted in significant enhancement of sensor-
imotor function compared with hAMSC-treated rats. Unlike
in the previous study, hAMSC-NSCs produced higher levels
of neurotrophic factors (nerve growth factor [NGF], BDNF,
NT-3, GDNF, ciliary neurotrophic factor [CNTF]) than
hAMSCs, again suggesting that cell replacement is unlikely.
Instead, a neuroprotective effect, associated with neuro-
trophic factors released by the grafted cells, may contribute
to functional recovery.
In a similar study where 20,000 neural stem cells differ-
entiated from hUCB (hUCB-NSCs) were intracerebrally
infused 48 h after photothrombotic stroke, extensive migra-
tion of the cells into brain-damaged cortex in the first week
after transplant was observed. However, differentiation was
observed in very few cells and cell survival in the brain
decreased gradually76. Again, this suggests that the persis-
tence of cells in the host brain is not required and differen-
tiation does not seem the main mechanism of action.
Therapeutic hypothermia can reduce functional deficits
and limit secondary damage in models of TBI77. In order
to potentially enhance therapeutic efficacy, Tu and col-
leagues combined hypothermia and hUCT-MSC treatments
in a rat model of severe TBI78. Temperature-sensitive
hUCT-MSCs were generated in order to promote the sur-
vival and the activity of grafted cells in the hypothermic rats
by infecting cells with a retrovirus carrying the temperature-
sensitive tsA58 SV40 LT antigen gene. Hypothermia con-
tributed to the survival, migration, and proliferation of
ts-hUCT-MSCs up to 28 d after injection in the lesion cavity,
promoting the improvement in sensorimotor and cognitive
functions more than hUCT-MSC therapy alone78.
Another approach used to establish an optimal environ-
ment to support lasting viability of stem cells in situ is the
use of engineered scaffolds, which make it possible to
deliver cells appropriately to the injured site, optimizing
their therapeutic effects. Huang and colleagues combined
hUCT-MSCs overexpressing CXCR4 fused to green fluor-
escent protein (hUCT-MSCCXCR4/GFP), responsible for cell
migration through SDF-1 signaling and usually present at
low levels on MSC membrane, with a chitosan scaffold
linked to recombinant BDNF79. The scaffold containing
hUCT-MSCCXCR4/GFP was transplanted in the lesion cavity
of TBI rats. CXCR4 overexpression stimulated hUCT-MSC
migration toward the lesion site, and the BDNF released
from scaffolds favored the differentiation of transplanted
cells into neurons, contributing to the regeneration of brain
tissue at the lesion boundary.
The same researchers developed another type of scaffold,
RADA16-BDNF, a self-assembling peptide hydrogel that
favored the differentiation of hUCT-MSCs into MAP-2-
positive neuronal cells80. When hUCT-MSCs were
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cocultured with lipopolysaccharide (LPS)-activated astro-
cytes, the percentage of MAP-2-positive cells was higher
and typical neuron-like cells with neurites extending in 3-
D directions differentiated from hUCT-MSCs. RADA16-
BDNF scaffolds embedded with hUCT-MSCCXCR4/GFP and
LPS-activated astrocytes were then transplanted into the
lesion cavity of rats subjected to moderate (2-mm-diameter)
and large (5-mm-diameter) lesions. hUCT-MSCCXCR4/GFP
migrated from the scaffold to the injured tissue, with a lesion
size–dependent efficacy in reducing the lesion size80.
Transgenically modified hUCT-MSCs engineered to
overexpress hepatocyte growth factor (hUCT-MSCsHGF)
have been used to enhance the therapeutic potential for ICH
damage81. hUCT-MSCs or hUCT-MSCsHGF (600,000) were
transplanted ICV 7 d after ICH, modeled by collagenase VII
injected into the left internal capsule. Both transplanted
groups showed better motor performance than untreated ani-
mals, and hUCT-MSCHGF-transplanted rats demonstrated a
greater functional recovery than hUCT-MSC-transplanted
rats. Neurological recovery was coupled with nerve fiber
remyelination (upregulation of myelin basic protein(MBP))
and axonal regeneration (upregulation of growth-associated
protein 43 (GAP-43)), demonstrating the pivotal role of
growth factors in placenta-derived stem cell–induced
protection.
To conclude, different strategies have been developed to
enhance the therapeutic effects of transplanted cells. Under-
standing the mechanisms of protection induced by placenta-
derived stem cells will help identify the best strategy for
maximizing their effect.
Placenta-Derived Cell Secretome: Toward
Cell-Free Therapy
The beneficial effects of cell therapy for acute brain injury
are mediated by the release of soluble factors with multilevel
effects providing support for surviving host cells, offering
protection from toxic stimuli from the damaged brain tissue,
and stimulating endogenous protective/reparative mechan-
isms. The view of secreted factors as mediators of brain
protection raises the possibility of a cell-free therapeutic
strategy, overcoming important issues related to intrinsic
cell heterogeneity and safety concerns. In vitro29,82–86 and
in vivo86–88 evidence shows that the conditioned medium
(CM) from placenta-derived cell cultures can induce effects
similar to the cell counterparts, demonstrating the feasibility
of this approach. The CM composition is influenced by dif-
ferent factors: besides the organ of origin and the donor’s
genetic background, several variables (i.e., cell density, cell
passage, culture medium, days of collection, presence of
preconditioning stimuli) may affect the release of soluble
molecules. We recently provided evidence of comparable
protective effects of hAMSC and CM treatments, indicating
that cross talk between hAMSCs and the damaged tissue is
not vital for the release of bioactive factors29. However,
whether the in vivo challenge to the transplanted cells
enhances or otherwise changes the release of their bioactive
factors calls for further investigations.
A number of cell-released soluble factors have been pro-
posed as mediators of the protection, and different classes of
molecules have been investigated (Figure 2). Among the
different classes of molecules that could be released in the
secretome, the proteic component is the most widely inves-
tigated. A recent review by Bai and colleagues provided an
overview of the secretion properties of umbilical-MSCs89,
identifying more than 90 cytokines belonging to the families
of ILs, TNFs, IFNs, colony-stimulating factors, growth fac-
tors, and chemokines. These proteins have important poten-
tial interest for brain pathologies, in view of their numerous
physiological functions, executing anti-inflammatory and
immunomodulatory effects; arousing angiogenesis, wound
healing, and neurogenesis; and stimulating antiapoptotic,
Figure 2. Categories of molecules secreted by placenta-derived stem cells.
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antiscarring, and matrix remodeling effects89. Pires and col-
leagues also identified other classes of proteins released by
UCT-MSCs involved in protection against oxidative stress,
anti-excitotoxicity effects, proteasomal degradation, and
regulators of toxic protein deposition90.
Nucleic acids are another class of molecules that have
recently aroused great interest. MicroRNAs (miRs) are small
noncoding sequences of RNA that can regulate the gene
expression of target cells and are being studied for therapy
as they play a key role in pathology. Packaged inside extra-
cellular vesicles, miR can be released into the extracellular
space and mediate nonhormonal intracellular communica-
tion91. The miR profile of UCT-MSCs was recently
characterized, with distinct expression from fibroblasts92.
Forty-two miRs have been found to be expressed differently
in UCT-MSCs and fibroblasts, and among the 15 that were
upregulated, miR-21, miR-146a, and miR-181 displayed the
most significant expression. Analysis of the downstream tar-
gets unraveled the involvement of these miRs in the inflam-
matory pathways, regulating macrophage phenotype and
inflammation ablation for tissue repair93–95. In the brain,
miR-21 mediates neuronal and microglial survival after
ischemic injury, reducing the levels of the apoptosis-
inducing factor Fas ligand96,97; miR-181 regulates the
expression of IL-10 anti-inflammatory cytokines in astro-
cytes98 and reduces the neuronal apoptosis induced by
microglia activated after an ischemic insult, suppressing
TNF-a expression99.
Another hUCB-MSC-released miR involved in neurores-
torative effects is miR-126100, which is vital for regulating
the function of endothelial cells, angiogenesis, and vascular
integrity101. Chen and colleagues showed that hUCB-MSC
treatment of stroke in type 2 diabetes mellitus mice restored
the serum and cerebral levels of miR-126, which was down-
regulated after injury100. Cell therapy promotes vascular
remodeling and angiogenesis and reduced brain hemorrhage
and BBB leakage. These effects were coupled with white
matter remodeling, anti-inflammatory effects, and a gener-
ally better functional outcome. All of these effects were
significantly attenuated in mice treated with hUCB-MSCs
in which miR-126 expression was inhibited, indicating an
important role for this miR in hUCB-MSC-induced
protection100.
Metabolites are small molecules (molecular weight
<2,000 Da) that include endogenous compounds (peptides,
lipids, amino acids, nucleic acids, carbohydrates, organic
acids, vitamins) or exogenous compounds (food additives,
drugs, toxins, pollutants, and other chemicals that humans
come into contact with)102. It is not easy to define the meta-
bolomics profile of human cells because thousands of com-
pounds belong to this class. In an in vitro model of acute
brain injury obtained by exposing cortical organotypic brain
slices to oxygen-glucose deprivation, we have recently
demonstrated that the CM from hAMSCs was protective,
and we identified a CM subfraction containing small meta-
bolites (molecular weight <700 Da) with marked protective
properties29. We further analyzed the CM active subfraction,
by profiling 6 metabolic classes, and identified a pool of
selectively enriched metabolites. These included molecules
such as lysine, taurine, a-aminoadipic-acid, and spermidine,
for all of which neuroprotective effects have been
reported103–107. However, our metabolomics analysis was
targeted a priori; thus, we cannot exclude that additional
metabolites with protective potential are present in the
CM subfraction. Another metabolite that is attracting
interest for the protection induced by stem cells is prosta-
glandin E2 (PGE2). PGE2 is highly secreted by placenta-
derived stem cells7,108–110, and there is increasing evidence
of its immunosuppressive effects on lymphocytes109,111–113
and monocytes/macrophages114,115 and a role for brain
protection116–119.
To conclude, the secretome of placenta-derived stem cells
holds great promise for the treatment of acute brain injury.
Different molecules have been identified as possible drivers
of beneficial effects. The exact mechanisms of action are
still not clear and numerous factors, rather than any single
one, probably contribute synergistically to the neuroprotec-
tive effects.
Clinical Use of Placenta-Derived Cells
in Acute Brain Injury
Placenta-derived stem cells are still only at their dawn in the
clinical setting compared to the more widely used bone mar-
row–derived stem cells, so only a few studies investigating
the feasibility and safety of this approach for acute brain
injury have been conducted so far (Table 1).
hUCB-derived stem cells for acute brain injury were first
used as an experimental neurorestorative treatment in a
16-mo-old child in a permanent vegetative state resulting
from a cardiac arrest–induced global hypoxic/ischemic brain
injury when he was 9 mo old120. The child had his own
hUCB deposited in a blood bank; autologous hUCB cells
were isolated and committed to neuronal lineage (hUCB-
NSCs), then labeled with supermagnetic iron oxide (SPIO)
and ICV transplanted. The child underwent 4 transplanta-
tions of 12 million hUCB-NSCs each, the first was when
he was 16 mo old, followed by 3 consecutive monthly injec-
tions. Magnetic resonance imaging (MRI) monitoring 24 h
posttransplant showed hUCB-NSCs extending along the
ependyma of the lateral ventricle. The SPIO signal progres-
sively decreased but was still visible 7 d, 1 mo, and 2 mo
after transplant, and disappeared by 4 mo. There were no
signs of brain edema, hemorrhage, or tumor in the 6 mo of
observation120 or in the follow-up at 33 mo121. The only side
effect was transient moderate fever the day after transplant.
Thus, the authors affirm the feasibility and the safety of
intracerebral transplant of hUCB-NSCs in the brain.
Jiang and colleagues ran a pilot study to assess the safety
of hUCT-MSCs delivered by a catheter through perilesional
vessels to treat stroke of the MCA territory, in order to
release more stem cells to the infarcted area compared to
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the more commonly used intravenous transplantation122.
Four males (between 40 and 59 y) with stroke (3 ischemic
and 1 hemorrhagic) were treated with 20 million hUCT-
MSCs between 11 and 50 d after the stroke onset. Patients
were monitored for the presence of additional ischemic
strokes: angiography 20 min after cell delivery did not indi-
cate any new blood flow impairment and MRI prior to dis-
charge did not reveal any new infarct. After transplant, there
was no sign of immune response (fever or rash), demonstrat-
ing the feasibility of intra-arterial delivery of hUCT-MSCs.
The trial was not powered to assess hUCT-MSC efficacy and
no conclusions could be drawn about the therapeutic
potential.
Chen and colleagues employed a multiple cell transplan-
tation approach for stroke patients in the chronic phase123.
Ten stroke patients (6 ischemic and 4 hemorrhagic), aged 42
to 87 y, were transplanted with different cell populations:
olfactory ensheathing cells from aborted human fetal olfac-
tory bulbs, Schwann cells from aborted human fetal sciatic
nerve, neural progenitor cells from aborted human subepen-
dymal zone of fetal brain, and/or hUCT-MSC collected after
birth. Patients received one or more doses of cells, ranging
from 1 to 23 million cells, using different delivery routes
(intracranial, intrathecal, or intravascular) and different
intervals from stroke onset (from 6 mo to 20 y). These het-
erogeneous treatments/protocols led to no adverse events
during or after the procedure or during the long-term
follow-up. The authors state that all patients achieved some
degree of improvement in neurological function, speech,
muscle tension, balance, pain relief, and respiratory stability.
Again, the small sample size limits the value of the findings
on combinatory cell therapy, so the results must be inter-
preted with caution.
A retrospective analysis compared the effect of human
bone marrow-derived mesenchymal stromal cells (hBM-
MSCs) and hUCT-MSCs or a conventional surgical
approach for ICH124. A total of 24 patients were treated with
conventional hematoma removal surgery within 6 h of the
hemorrhage. Patients scheduled for MSC treatment received
2 transplants of hBM-MSCs (n ¼ 7) or hUCT-MSCs (n ¼ 9)
into the hematoma cavity 2 and 3 wk after injury. All the
transplanted patients had a shorter hematoma reabsorption
time and a better outcome at 5 y than untreated patients.
Importantly, patients receiving hUCT-MSCs had a better
outcome than hBM-MSC-treated patients starting from
3 mo after injury, suggesting that placenta-derived stem cells
have higher therapeutic potential than adult stem cells124.
Only one clinical study using placenta-derived stem cells
in TBI has been published125. Forty patients with TBI at
chronic stages (range: 1-11 y post-TBI) were randomly allo-
cated to treatment with hUCT-MSCs or vehicle, and follow-
up was obtained at 6 mo posttreatment. Twenty patients in
the stem cell group received 4 hUCT-MSC transplants, each
containing 10 million stem cells (over an interval of 5-7 d)
by lumbar puncture. All patients were analyzed by Fugl-
Meyer assessment (FMA)126, a multi-item scale assessing
motor function, sensory function, balance, joint range of
motion, and joint pain, and by Functional Independence
Measure (FIM)127, a multi-item rating scale assessing self-
care, bowel and bladder management, mobility, communi-
cation, cognition, and psychosocial adjustment. During stem
cell transplantation, patients were monitored for body tem-
perature, heart rates, blood pressures, oxygen saturations,
and respiratory rates, and no obvious abnormalities were
found. Four (20%) patients experienced headache and mild
dizziness within 48 h post lumbar puncture. At 6 mo, patients
received head and spinal cord MRI examinations and no
abnormalities related to the stem cell transplantation were
found. Rating scales at 6 mo indicated that while the control
group had FMA and FIM scores not significantly different
from the baseline time point, the hUCT-MSC-treated
patients had slightly better FMA and FIM scores125. Thus,
the preliminary findings of the therapeutic potential of
hUCT-MSCs demonstrate the feasibility and safety of this
approach for acute brain injury. Further research is now
needed to validate and strengthen these results in order to
offer cell therapy for patients with acute brain injury.
Currently, 8 ongoing phase I or II clinical trials are pres-
ent in the world’s largest registry clinicaltrials.gov using
placenta-derived stem cells for acute brain injuries (Table
2). Seven trials target stroke, 1 cerebral hemorrhage, and
none have been designed for TBI. All trials are single center
and use UC-derived stem cells. Three trials are designed as
single-group assignment open label, 2 as randomized open
label, and 3 as randomized double-blind placebo-controlled
trials. Thus, several conclusions will be drawn at the end of
these trials, posing the bases for the construction of a larger
phase 3 trial.
Conclusions
There is growing experimental evidence for the efficacy of
placenta-derived stem cells for acute brain injury. The multi-
target potential of cell therapy fulfills the need of the dam-
aged brain in which numerous injury mechanisms are
triggered. Infused cells can reprogram the local inflamma-
tory microenvironment from detrimental to beneficial,
favoring protective/pro-regenerative changes in the lesioned
tissue and contributing to permanent improvement in neuro-
logical function. Even in case of predifferentiation into neu-
ronal lineage, cell replacement is unlikely, whereas the main
mechanisms of action through which infused cells confer
protection is through the secretion of bioactive factors, sug-
gesting the potential for a cell-free strategy based on the cell
secretome. Different classes of molecules have been identi-
fied as mediators of protective effects. However, the pool of
factors sufficient and necessary to promote brain protection/
repair has not yet been pinpointed and further studies are
needed to identify a controlled, standardized “secretome-
based” cell-free strategy. Clinical studies are in their infancy,
with few reports demonstrating the safety and preliminary
efficacy of cell transplantation. The ongoing trials are crucial
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to assess the efficacy of placenta-derived stem cells for acute
brain injury.
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